- Report
- April 2025
- 83 Pages
Canada
From €3186EUR$3,500USD£2,706GBP
- Report
- October 2023
- 140 Pages
Europe
From €3641EUR$4,000USD£3,092GBP
- Report
- February 2024
- 130 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- January 2025
- 28 Pages
Spain
From €1700EUR$2,001USD£1,494GBP
- Report
- January 2022
- 52 Pages
Europe
From €1100EUR$1,295USD£967GBP
- Report
- December 2020
- 63 Pages
Germany
From €548EUR$624USD£450GBP
- Book
- April 2019
- 836 Pages
Canada
- Report
- September 2022
- 250 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
The recreational cannabis market has become a notable segment within the broader analgesics industry, as consumers increasingly seek alternatives to traditional over-the-counter and prescription pain relievers. Cannabis is touted for its pain-relieving properties, with THC and CBD being the most prominent constituents associated with analgesic effects. Recreational cannabis offers a dual benefit of alleviating pain and providing a pleasurable experience, which has led to its rising popularity where it is legally permitted. It is available in various forms, including but not limited to flower, edibles, oils, and topicals. Consumers can choose products based on desired effect, potency, and mode of consumption. The market's expansion is further driven by ongoing research and development aimed at understanding the therapeutic potential of cannabis and optimizing its use for pain management.
Several companies have established their presence in the recreational cannabis market with a focus on analgesic products. Well-known players include Canopy Growth Corporation, Aurora Cannabis, and Tilray, all of which have extensive product lines and international reach. Other notable companies are Curaleaf and Cresco Labs, which have a strong presence in the United States. These companies are engaged in competitive strategies, including product innovation and mergers & acquisitions, to capture a larger share of the market. Show Less Read more